MedPath

Tamsulosin

Generic Name
Tamsulosin
Brand Names
Flomax, Jalyn
Drug Type
Small Molecule
Chemical Formula
C20H28N2O5S
CAS Number
106133-20-4
Unique Ingredient Identifier
G3P28OML5I
Background

Tamsulosin is a selective alpha-1A and alpha-1B adrenoceptor antagonist that exerts its greatest effect in the prostate and bladder, where these receptors are most common. It is indicated for the treatment of signs and symptoms of benign prostatic hypertrophy. Antagonism of these receptors leads to relaxation of smooth muscle in the prostate and detrusor muscles in the bladder, allowing for better urinary flow. Other alpha-1 adrenoceptor antagonists developed in the 1980s were less selective and more likely to act on the smooth muscle of blood vessels, resulting in hypotension.

Tamsulosin was first approved by the FDA on April 15, 1997.

Indication

Tamsulosin is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia.

Tamsulosin is also used off label for the treatment of ureteral stones, prostatitis, and female voiding dysfunction.

Associated Conditions
Benign Prostatic Hyperplasia (BPH), Benign Prostatic Hypertrophy, Bladder Outlet Obstruction, Ureteral Calculus

Proof-of-concept Study to Evaluate the Safety and Efficacy of Tryptophan in Patients with BPH.

Phase 2
Recruiting
Conditions
BPH
LUTS(Lower Urinary Tract Symptoms)
Interventions
Drug: 5-hidroxitriptophan
First Posted Date
2022-06-02
Last Posted Date
2025-01-06
Lead Sponsor
Clinical Academic Center (2CA-Braga)
Target Recruit Count
70
Registration Number
NCT05401032
Locations
🇵🇹

Clinical Academic Center - Braga, Association (2CA-Braga), Braga, Portugal

Tamsulosin Assisted Ureteral Access Sheath Insertion

Phase 3
Conditions
Renal Stone
Retrograde Intrarenal Surgery
Urolithiasis
Interventions
First Posted Date
2022-01-19
Last Posted Date
2022-01-19
Lead Sponsor
Sengkang General Hospital
Target Recruit Count
110
Registration Number
NCT05197088

Role of Antihistaminic in Acute Renal Colic Prevent Pain Recurrence and Expulsion of Ureteric Stone ≤ 1cm

Conditions
Ureter Stone
Renal Colic
Interventions
First Posted Date
2021-12-09
Last Posted Date
2021-12-09
Lead Sponsor
Assiut University
Target Recruit Count
100
Registration Number
NCT05150899

Medical Expulsive Therapy Post-SWL For Renal Stones

Not Applicable
Completed
Conditions
Urologic Diseases
Urolithiasis
Stone, Kidney
Interventions
Drug: Placebo
First Posted Date
2021-09-02
Last Posted Date
2021-09-02
Lead Sponsor
Mansoura University
Target Recruit Count
235
Registration Number
NCT05032287
Locations
🇪🇬

Urology and Nephrology Center, Mansourah, Aldakahlia, Egypt

Post-Operative Urinary Retention (POUR) in Thoracic Surgery Patients Receiving Prophylactic Tamsulosin

Phase 4
Terminated
Conditions
Thoracic Diseases
Urinary Retention
Interventions
First Posted Date
2021-08-06
Last Posted Date
2024-11-07
Lead Sponsor
University of Massachusetts, Worcester
Target Recruit Count
109
Registration Number
NCT04994431
Locations
🇺🇸

UMass Memorial Healthcare, Inc., Worcester, Massachusetts, United States

Investigating Medication vs. Prostatic Urethral Lift: Assessment and Comparison of Therapies for BPH

Phase 4
Recruiting
Conditions
BPH
Interventions
Device: UroLift System
First Posted Date
2021-08-03
Last Posted Date
2023-04-25
Lead Sponsor
NeoTract, Inc.
Target Recruit Count
250
Registration Number
NCT04987892
Locations
🇺🇸

Neotract, Pleasanton, California, United States

Pre-operative Tamsulosin and Time to Spontaneous Void After Hysterectomy

Phase 2
Completed
Conditions
Urinary Retention Postoperative
Interventions
Drug: Placebo
First Posted Date
2021-04-26
Last Posted Date
2024-02-29
Lead Sponsor
University of Arizona
Target Recruit Count
161
Registration Number
NCT04859660
Locations
🇺🇸

Banner University Medical Center- Phoenix, Phoenix, Arizona, United States

🇺🇸

Banner University Medical Center- Tucson, Tucson, Arizona, United States

Tamsulosin as Adjunctive Therapy After Extracorporeal Shock Wave Lithotripsy for Renal Stones

Phase 4
Completed
Conditions
Renal Stone
Interventions
Procedure: Extracorporeal shock wave lithotripsy
First Posted Date
2021-03-29
Last Posted Date
2021-04-01
Lead Sponsor
Hospital Regional de Alta Especialidad del Bajio
Target Recruit Count
60
Registration Number
NCT04819828

The Effect of Tamsulosin on Postoperative Urinary Retention

Phase 4
Terminated
Conditions
Urinary Retention
Interventions
Drug: Placebo
First Posted Date
2020-12-23
Last Posted Date
2024-01-31
Lead Sponsor
Wake Forest University Health Sciences
Target Recruit Count
4
Registration Number
NCT04682366
Locations
🇺🇸

Wake Forest Health Sciences, Winston-Salem, North Carolina, United States

Impact of Tamsulosin on Post-Operative Urinary Retention Following Pelvic Reconstructive Surgery

Phase 2
Recruiting
Conditions
Urinary Retention Postoperative
Interventions
Drug: Placebo
First Posted Date
2020-10-22
Last Posted Date
2025-02-14
Lead Sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Target Recruit Count
154
Registration Number
NCT04597372
Locations
🇺🇸

West Penn Hospital, Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath